Serina Therapeutics closed at $1.69 on Nov 4, down 7.65%, 63.9% below its 52-week closing high. Volume of 39.6K shares was 0.77× its 20-day average (below normal).
Split-adjusted performance: -17.2% over one month, -7.7% over six months, -63.9% over one year.
Short interest was 43.9K shares at the Oct 15 settlement, down 22.5% from the prior report (0.6% of float, 1.1 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SERSerina Therapeutics | $1.69 | −7.65% | −7.7% | −100.0% | — | — | $42.9M | |
| ELTXElicio Therapeutics | $1.56 | +2.63% | −85.1% | — | — | — | $42.3M | Compare |
| ATNMActinium Pharmaceuticals | $1.41 | +0.71% | +13.7% | — | 79.7% | 3.9 | $44.3M | Compare |
| BMEABiomea Fusion | $0.6119 | −1.91% | −61.8% | — | — | — | $44.4M | Compare |
| HYPDHyperion DeFi | $3.07 | +0.66% | −15.7% | — | 4009.1% | — | $46.7M | Compare |
| DWTXDogwood Therapeutics | $1.03 | −0.96% | −37.6% | — | — | — | $39.4M | Compare |
| ALDXAldeyra Therapeutics | $0.6474 | +4.32% | −62.8% | — | — | — | $39.1M | Compare |
| INMInMed Pharmaceuticals | $8.75 | +420.83% | +1104.6% | — | — | — | $48.1M | Compare |
| SCYXSCYNEXIS | $3.84 | −2.54% | −51.1% | −82.8% | 3147.7% | — | $38.2M | Compare |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
